Skip to main content
. 2020 Dec 11;55(Suppl 1):181–714. doi: 10.1038/s41409-020-01120-w
Donor MRD 30 (28%) MUD 31 (29%) MMRD 47 (43%)
GvHD prophylaxis CsA-based 25 (23%) Sirolimus-based 87 (76%) Other 1 (1%)
chGvHD type Classic 61 (56%) Overlap 47 (44%)
chGvHD grade Mild 13 (12%) Moderate 39 (36%) Severe 56 (52%)
IR score Low 38 (35%) Intermediate 27 (25%) High 28 (26%) not evaluable 15 (14%)

[Table 1. Patients characteristics]